Literature DB >> 17178844

Ataxia telangiectasia mutated down-regulates phospho-extracellular signal-regulated kinase 1/2 via activation of MKP-1 in response to radiation.

Mukesh K Nyati1, Felix Y Feng, Divya Maheshwari, Sooryanarayana Varambally, Steven P Zielske, Aarif Ahsan, Patrick Y Chun, Vinay A Arora, Mary A Davis, Mira Jung, Mats Ljungman, Christine E Canman, Arul M Chinnaiyan, Theodore S Lawrence.   

Abstract

Ataxia telangiectasia mutated (ATM) kinase plays a crucial role in the cellular response to DNA damage and in radiation resistance. Although much effort has focused on the relationship between ATM and other nuclear signal transducers, little is known about interactions between ATM and mitogenic signaling pathways. In this study, we show a novel relationship between ATM kinase and extracellular signal-regulated kinase 1/2 (ERK1/2), a key mitogenic stimulator. Activation of ATM by radiation down-regulates phospho-ERK1/2 and its downstream signaling via increased expression of mitogen-activated protein kinase phosphatase MKP-1 in both cell culture and tumor models. This dephosphorylation of ERK1/2 is independent of epidermal growth factor receptor (EGFR) activity and is associated with radioresistance. These findings show a new function for ATM in the control of mitogenic pathways affecting cell signaling and emphasize the key role of ATM in coordinating the cellular response to DNA damage.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17178844     DOI: 10.1158/0008-5472.CAN-06-1935

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Implementation of high-content assay for inhibitors of mitogen-activated protein kinase phosphatases.

Authors:  Andreas Vogt; John S Lazo
Journal:  Methods       Date:  2007-07       Impact factor: 3.608

2.  EGF receptor and PKCδ kinase activate DNA damage-induced pro-survival and pro-apoptotic signaling via biphasic activation of ERK and MSK1 kinases.

Authors:  Angela M Ohm; Trisiani Affandi; Mary E Reyland
Journal:  J Biol Chem       Date:  2019-01-24       Impact factor: 5.157

3.  ATM-dependent ERK signaling via AKT in response to DNA double-strand breaks.

Authors:  Ashraf Khalil; Rhiannon N Morgan; Bret R Adams; Sarah E Golding; Seth M Dever; Elizabeth Rosenberg; Lawrence F Povirk; Kristoffer Valerie
Journal:  Cell Cycle       Date:  2011-02-01       Impact factor: 4.534

Review 4.  Dual-specificity phosphatases: therapeutic targets in cancer therapy resistance.

Authors:  Zahra Zandi; Bahareh Kashani; Zivar Alishahi; Atieh Pourbagheri-Sigaroodi; Fatemeh Esmaeili; Seyed H Ghaffari; Davood Bashash; Majid Momeny
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-04       Impact factor: 4.553

5.  Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.

Authors:  Christina I Tsien; Mukesh K Nyati; Aarif Ahsan; Susmita G Ramanand; Douglas B Chepeha; Francis P Worden; Joseph I Helman; Nisha D'Silva; Carol R Bradford; Gregory T Wolf; Theodore S Lawrence; Avraham Eisbruch
Journal:  Head Neck       Date:  2012-08-21       Impact factor: 3.147

6.  Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity.

Authors:  Toshimitsu Tanaka; Anupama Munshi; Colin Brooks; Jenny Liu; Marvette L Hobbs; Raymond E Meyn
Journal:  Clin Cancer Res       Date:  2008-02-15       Impact factor: 12.531

7.  Role of cell cycle in epidermal growth factor receptor inhibitor-mediated radiosensitization.

Authors:  Aarif Ahsan; Susan M Hiniker; Mary A Davis; Theodore S Lawrence; Mukesh K Nyati
Journal:  Cancer Res       Date:  2009-06-09       Impact factor: 12.701

8.  Functional and molecular interactions between ERK and CHK2 in diffuse large B-cell lymphoma.

Authors:  Bojie Dai; X Frank Zhao; Krystyna Mazan-Mamczarz; Patrick Hagner; Sharon Corl; El Mustapha Bahassi; Song Lu; Peter J Stambrook; Paul Shapiro; Ronald B Gartenhaus
Journal:  Nat Commun       Date:  2011-07-19       Impact factor: 14.919

9.  Recovery From Rheumatoid Arthritis Following 15 Months of Therapy With Low Doses of Ionizing Radiation: A Case Report.

Authors:  Shuji Kojima; Mitsutoshi Thukimoto; Jerry M Cuttler; Kiyomi Inoguchi; Takahiro Ootaki; Noriko Shimura; Hironobu Koga; Akihisa Murata
Journal:  Dose Response       Date:  2018-07-08       Impact factor: 2.658

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.